Research programme: companion diagnostic tests - Abbott/GlaxoSmithKline

Drug Profile

Research programme: companion diagnostic tests - Abbott/GlaxoSmithKline

Latest Information Update: 30 Nov 2011

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; GlaxoSmithKline Biologicals
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 30 Nov 2011 MAGE-A3 diagnostic test is still in preclinical trials for diagnosis of Malignant melanoma and Non-small cell lung cancer in USA
  • 29 Nov 2011 Abbott expands its agreement with GlaxoSmithKline to include another companion diagnostic test for the PRAME antigen
  • 03 Mar 2010 Preclinical trials in Malignant melanoma (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top